Alpha-fetoprotein as a predictor of hepatocellular carcinoma recurrence following liver transplantation

Abstract

Alpha-fetoprotein (AFP) has been increasingly recognised as a valuable marker in predicting HCC recurrence post-liver transplantation. Moreover, its secretion has been associated with poor histological tumour characteristics as it reflects an aggressive tumour biological behaviour. This review aims to summarise the emerging evidence on the use of AFP either as an independent marker, or as a variable incorporated into prognostic models. For this purpose, an electronic PubMed literature search was performed. Due to the heterogeneity of the reported studies, drawing clear conclusions about the optimum AFP cut-off level to predict recurrence is difficult. Models that include AFP at different cut-offs have been shown be superior to Milan criteria in predicting disease recurrence, but need to be prospectively validated in order to confirm their prognostic value. Until more refined methods for selecting patients become available, existing evidence support the use of AFP in decision models for liver transplantation.

Keywords

Alpha-fetoprotein / hepatocellular carcinoma / liver transplantation / recurrence / survival

References

[1] Yang JD,Watt KD,Wiesner RH,Roberts LR,Leise MD.Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States.Clin Gastroenterol Hepatol2017;15:767-75 PMCID:PMC5401787

[2] European Association for the Study of the Liver..Electronic address: [e-mail]; European Association for the Study of the Liver. EASL practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[3] Mazzaferro V,Doci R,Pulvirenti A,Montalto F,Morabito A.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med1996;334:693-9

[4] Lerut J.Morphology does not tell us the entire story: biological behavior improves our ability to select patients with hepatocellular carcinoma waiting for liver transplantation.Hepatobiliary Pancreat Dis Int2015;14:570-1

[5] Lai Q,Melandro F,Rossi M.The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution.Transl Gastroenterol Hepatol2017;2:72 PMCID:PMC5639034

[6] Merani S,Kneteman NM,Morel P,Toso C.The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.J Hepatol2011;55:814-9

[7] Mazzaferro V,Zhou J,De Carlis L,Cescon M,Yi-Feng H,Bongini M.Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma.Gastroenterology2018;154:128-39

[8] Mehta N,Harnois DM,Dodge JL,Burns JM,Greig PD,Roberts JP.Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant.JAMA Oncol2017;3:493-500 PMCID:PMC5395317

[9] Toso C,Hernandez-Alejandro R,Marotta P,Kneteman NM.Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation.Hepatology2015;62:158-65

[10] Duvoux C,Decaens T,Badran H,Francoz C,Vanlemmens C,Dharancy S,Bernard PH,Radenne S,Conti F,Pageaux GP,Salame E,Lebray P,Debette-Gratien M,Mallat A,Cherqui D.Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria.Gastroenterology2012;143:986-94

[11] Hameed B,Sapisochin G,Yao FY.Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.Liver Transpl2014;20:945-51 PMCID:PMC4807739

[12] Lai Q,Graziadei I,Rossi M,Goffette P,Pitton MB.Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.Liver Transpl2013;19:1108-18

[13] Mehta N,Roberts JP.Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.Am J Transplant2018;18:1206-13

[14] Hakeem AR,Marangoni G,Prasad KR.Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma.Aliment Pharmacol Ther2012;35:987-99

[15] Berry K.Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.Liver Transpl2013;19:634-45

[16] Lai Q,Manzia TM,Agnes S,Berloco PB.Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation.Clin Transplant2012;26:E125-31

[17] Vibert E,Hoti E,Samuel D,Lemoine A,Castaing D.Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor.Am J Transplant2010;10:129-37

[18] Lai Q,Iesari S,Mennini G,Hoppe-Lotichius M,Manzia TM,Avolio AW,Graziadei I,Tsochatzis E,Ettorre GM,Vivarelli M,Cillo U.Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer.Hepatology2017;66:1910-19

[19] Toso C,Bigam DL,Kneteman NM.Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database.Hepatology2009;49:832-8

[20] Ciccarelli O,Goffette P,De Reyck C,Sempoux C,Reding R.Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients.Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int2012;25:867-75

[21] Zheng SS,Wu J,Wang WL,Liang TB.Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.Transplantation2008;85:1726-32

[22] McHugh PP,Vera S,Ranjan D.Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.HPB (Oxford).2010;12:56-61 PMCID:PMC2814405

[23] Grat M,Stypulkowski J,Krasnodebski M,Lewandowski Z,Patkowski W.The Warsaw proposal for the use of extended selection criteria in liver transplantation for hepatocellular cancer.Ann Surg Oncol2017;24:526-34 PMCID:PMC5215188

[24] Lee HW,Lee SG,Joh JW,Kim SI,Kim DS,Suh KS.Patient selection by tumor markers in liver transplantation for advanced hepatocellular carcinoma.Liver Transpl2018;;

[25] She WH,Cheung TT,Chok KSH.Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels.World J Hepatol2018;10:308-18 PMCID:PMC5838449

[26] Notarpaolo A,Magistri P,Colledan M,Miglioresi L,Vennarecci G,Burra P,Fagiuoli S,Maria Ettorre G,Cillo U,Katsahian S,Roudot-Thoraval F.Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.J Hepatol2017;66:552-59

[27] Pinero F,de Ataide EC,Marciano S,Anders M,Menendez J,Munoz L,Soza A,Poniachik J,Gadano A,Duvoux C.Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America.Liver Int2016;36:1657-67

[28] Vitale A,Burra P,Giannini EG,Piscaglia F,Di Marco M,Zoli M,Cabibbo G,Sacco R,Missale G,Gasbarrini A,Virdone R,Spolverato G.Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: a multicenter cohort study using the alpha-fetoprotein model as a survival predictor.Liver Transpl2015;21:1250-8

[29] Sasaki K,Hashimoto K,Diago-Uso T,Eghtesad B,Aucejo FN.Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.Lancet Gastroenterol Hepatol2017;2:595-603

[30] Lai Q,Inostroza Nunez M,Goffette P,Giovagnoni A,Lerut J.A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: time-radiological-response-alpha-fetoprotein-inflammation (TRAIN) score.Ann Surg2016;264:787-96

[31] Introduction to patient selection and organ allocation policies. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/4955/introduction_to_selection_and_allocation_policies.pdf. [Last accessed on 30 Aug 2018]

[32] Clavien PA,Bossuyt PM,Langer B.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.Lancet Oncol2012;13:e11-22